Company intelligence / Profile preview

NovoBiome

Ownership: Private
Development stage: Preclinical

Overview

NovoBiome is developing breakthrough Live Biotherapeutics Products targeting the gut-liver axis, with its lead candidate ADC-001 in preclinical development for NAFLD and NASH. The company leverages a proprietary ex-vivo platform, NovoSift®, to discover novel drug targets and candidates by simulating human intestinal physiology[1].

Therapeutic areas: Gastroenterology
Modalities: Live Biotherapeutic Products (LBPs)
Industry: Biotech

Drug pipeline

1 asset

ADC-001

Pre-clinical

Indications: NAFLD, NASH

Partnerships

Not specifically disclosed as of latest available information.

Beyond the preview

Go deeper on NovoBiome.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NovoBiome.

Explore the full profile